ARQT (Arcutis Biotherapeutics) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARQT Arcutis Biotherapeutics Inc ARQT
56 GF Score
Price $25.13
GF Value $30.59
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Arcutis Biotherapeutics Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

ARQT
56GF Score
Arcutis Biotherapeutics Inc ARQT
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arcutis Biotherapeutics (ARQT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcutis Biotherapeutics stock appears to be undervalued. The current stock price of $25.13 is trading 17.9% below its estimated GF Value™ of $30.59. GuruFocus considers Arcutis Biotherapeutics to be Modestly Undervalued.

Key valuation signals for ARQT:

  • Cash Payments:
  • GF Value™: $30.59 vs. price of $25.13 (17.9% below fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the ARQT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arcutis Biotherapeutics Business Description

Address 3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
56GF Score

Get the complete analysis for ARQT

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.13
Price
$30.59
GF Value